Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

As healthcare costs and procedure volumes continue to shift globally, investors must decide between two titans of the industry. Choosing between Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) requires weighing diversified stability against high-growth specialized technology.

Abbott provides a broad array of medical products used in daily care, while Intuitive focuses on the specialized niche of robotic-assisted surgery. These companies are often compared because they represent different ways to invest in the future of medical technology and hospital spending.

The case for Abbott Laboratories

Abbott Laboratories operates a diversified business model that spans diabetes care, cardiovascular devices, diagnostics, and nutrition. It sells products to a wide range of customers, including hospitals, wholesalers, and government agencies, which helps it weather fluctuations in any single market. In early 2026, the company entered a definitive agreement to acquire Exact Sciences to strengthen its presence in the cancer diagnostics market.

In FY 2025, revenue reached nearly $44.3 billion, representing a growth of roughly 5.7% compared to the previous year. The company reported net income of approximately $6.5 billion for the period, resulting in a net margin of close to 14.7%. This performance reflects steady demand across its various healthcare segments, particularly in its medical device and diagnostic divisions.

Abbott maintains a stable financial position with a debt-to-equity ratio of nearly 0.3x as of its December 2025 balance sheet. This ratio, which compares total debt to shareholder equity, suggests a conservative approach to borrowing. The company also reported a current ratio of roughly 1.6x, indicating it has enough short-term assets to cover its immediate liabilities. Free cash flow, or the cash left after paying for operating costs and capital expenditures, reached approximately $7.4 billion in FY 2025.

The case for Intuitive Surgical

Intuitive Surgical is the pioneer of robotic-assisted surgery, primarily through its da Vinci and Ion systems. The company operates a "razor and blade" business model, where the initial sale of a robotic system leads to years of recurring revenue from instruments, accessories, and maintenance services. Its primary customers are hospitals and ambulatory surgery centers, and it has recently expanded its direct sales reach into several European markets to improve its medical device stocks presence.

In FY 2025, revenue reached roughly $10.1 billion, which was a significant increase of approximately 20.5% over the prior year. Net income for the same period was close to $2.9 billion, yielding a strong net margin of nearly 28.4%. This robust profitability is driven by the high volume of surgical procedures performed using its installed base of robots worldwide.

As of its December 2025 balance sheet, the company has a debt-to-equity ratio of 0.0x, indicating that shareholder equity far exceeds its total debt. Its current ratio stands at approximately 4.9x, showing a very high level of liquidity to meet short-term obligations. Free cash flow for FY 2025 was nearly $2.5 billion. Note that stock-based compensation represented roughly 26% of operating cash flow, which inflates reported cash generation since SBC is a non-cash expense added back in the cash flow statement.

Risk profile comparison

Abbott Laboratories faces risks related to its complex manufacturing and supply chain, particularly its reliance on single-source suppliers for certain products. The company is also dealing with significant ongoing litigation involving product liability claims for infant formula and potential False Claims Act allegations. Intense competition from rivals like Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ) means Abbott must constantly innovate to protect its market share in the medical device and diagnostics sectors.

Intuitive Surgical faces competition from alternative surgical approaches and new robotic entrants like Medtronic and SS Innovations International (NASDAQ:SSII). Macroeconomic pressures could lead hospitals to tighten their capital spending budgets, potentially delaying the purchase of expensive new robotic systems. Additionally, the company is vulnerable to supply chain issues involving rare earth elements and must navigate increasingly strict global regulations regarding AI-enabled medical devices and patient data privacy.

Valuation comparison

Abbott Laboratories appears to be the more conservatively priced option, while Intuitive Surgical carries a higher premium due to its faster revenue growth.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

The Forward P/E ratio compares the current stock price to future earnings estimates, while the P/S ratio measures the market value against sales over the past twelve months.

Which stock would I buy in 2026?

I'd go with Intuitive Surgical. Its installed base of nearly 12,000 da Vinci surgical systems is a major, durable competitive advantage in healthcare. Once a hospital has trained its surgeons on the platform and built its workflows around it, switching is rarely worth the disruption. Recurring revenue accounts for roughly 85% of total revenue, procedures grew at a strong double-digit rate in the most recent quarter, and the company beat earnings estimates by a wide margin while raising its gross margin outlook.

Abbott Laboratories deserves credit for running a well-diversified healthcare business across medical devices, diagnostics, and nutrition, and its acquisition of Exact Sciences adds a more exciting diagnostics story. For investors who want broad healthcare exposure alongside a growing dividend, it is a solid choice.

But Intuitive is growing faster, with a more focused business and a platform that keeps deepening its relationships with every hospital that adopts it. For a patient investor, that compounding advantage is worth owning.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories, Intuitive Surgical, and Medtronic. The Motley Fool recommends the following options: long January 2028 $520 calls on Intuitive Surgical and short January 2028 $530 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.